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INTRODUCTION
Breast cancer is one of the major causes of cancer mortality in women.
Current therapies for breast cancer mainly target molecular signaling pathways that promote tumor cell proliferation and survival, facilitate angiogenesis or block cellular differentiation. An unexplored approach to breast cancer treatment is targeting of cellular energetics, which has long been known to be aberrant in malignant cells; yet its importance in cancer biology and treatment has often been neglected. It was first noted by Dr. Otto Warburg that cancer cells rely mainly on aerobic glycolysis to generate ATP instead of more efficient mitochondrial oxidative phosphorylation, resulting in the increased rate of glucose uptake and lactate production even in the presence of sufficient oxygen supply (1).
Eukaryotic elongation factor-2 kinase (eEF-2K), a negative regulator of protein synthesis (2), plays an important role in cell survival (3), and is overexpressed in breast cancer cell lines and human breast cancer specimens (4) . In this study, we tested whether eEF-2K was involved in the regulation of energy metabolism in breast cancer cells, and whether targeting eEF-2K rendered breast cancer cells less capable of coping with metabolic/ therapeutic stress and render them more sensitive to treatments.
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In the past grant period, I attended the following courses: To analyze whether eEF-2K plays a regulatory role in cellular energy metabolism in breast cancer cells, we silenced eEF-2K expression using siRNA in three human breast cancer cell lines (Fig. 1A) , and then measured ATP and lactate levels. As shown in Fig. 1B , inhibition of eEF-2 kinase by siRNA significantly decreased ATP level. As tumor cells rely mainly on glycolysis to generate energy instead of oxygen phosphorylation, and the level of lactate, and the final product of glycolysis, can be used to assay glycolytic activity (5), we compared the lactate levels in breast cancer cells with or without silencing of eEF-2K expression. We further found that inhibition of eEF-2K also resulted in reduction of lactate levels (Fig. 1C) . These results further support a role for eEF-2K in activating glycolysis in breast cancer cells.
We next tested whether eEF-2K plays a prosurvival role in response of breast cancer cells to a compromised supply of nutrients and growth factors. We knocked down eEF-2 kinase, and then compared the growth and survival of the cells with or without silencing of eEF-2K in serum-free medium or HBSS. As shown in Fig. 2A , suppression of eEF-2K hindered the tumor cell growth in the absence of serum. Knockdown of eEF-2K also caused more death of MCF-7 cells cultured in HBSS (Fig. 2B) . 
KEY RESEARCH ACCOMPLISHMENTS
• We found that silencing of eEF-2K caused a reduction of cellular ATP and lactate in human breast cancer cells.
• We showed that inhibition of eEF-2K decreased growth and survival of metabolically stressed breast cancer cells.
• We observed that suppression of eEF-2K sensitized breast cancer cells to growth factor inhibitors.
• We found that inhibition of eEF-2K enhanced apoptotic activities breast cancer cells in response to ER stress. 
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